

LIST OF TABLES

Table		Page
(I)	Recommended follow up schedule for DR	24
(II)	Different notation of visual acuity values as decimal values, snellen	29
(III)	Distribution of the studied cases according to demographic data	33
(IV)	Distribution of the studied cases according to DM	35
(V)	Mean, standard deviation and range of visual acuity before IVTA injection and after one month and six months from IVTA injection	37
(VI)	Mean, standard deviation and range of retinal thickness in central subfield zone before IVTA injection and after one month and six months from IVTA injection	39
(VII)	Mean, standard deviation and range of PROS length in macular grid zone before IVTA injection and after one month and six months from IVTA injection.	41
(VIII)	Mean, standard deviation and range of PROS length in central subfield zone before IVTA injection and after one month and six months from IVTA injection	44
(IX)	Mean standard deviation and range of PROS length in central foveal point before IVTA injection and after one month and six months from IVTA injection.	46
(X)	Correlation between VA with retinal thickness in the central subfield zone	47
(XI)	Correlation between VA and PROS in MG, CS and CFP	48

LIST OF FIGURES

Figure		Page
(1)	Retinal Anatomy and Mechanisms of Diabetic Retinopathy	5
(2)	Balance between angiostatic and angiogenic factors	6
(3)	Moderate NPDR showing circinate ring of hard exudates.	8
(4)	Severe NPDR showing venous beading.	8
(5)	Early PDR with NVD.	8
(6)	Advanced PDR showing fibrous proliferation.	8
(7)	PDR with PRH & VH.	8
(8)	CSME.	8
(9)	Optical interferometry; high resolution time and distance measuring by correlating one light beam with another	11
(10)	High resolution OCT image of a healthy fovea showing the layered structure of the retina	12
(11)	a- OCT image, horizontal line centered at fovea, scan length = 8 mm. Top: normal eye. Bottom: CSME patient, left side of the scan shows outer retinal spongy thickening, loss of the definition of the IS/OS line, and multiple highly reflective deposits with relative preservation of the foveal contour [TYPE 1]	15
	b- High-definition line scan (16x averaged lines) through the fovea.[TYPE 2]	16
	c- High-definition OCT of the fovea demonstrating vitreous traction, taut posterior hyaloid and subfoveal cholesterol. [TYPE 4]	17
(12)	Macular thickness means (SD) in ETDRS areas A1 - A9 measured using OCT in 20 eyes of 20 healthy individuals in Laursen et al study	18
(13)	OCT scans showing the morphological patterns of DME; simple thickening(A), mild CME (B), moderate CME (C), severe CME (D) and neuroepithelial detachment(E).	20
(14)	Grades of taut posterior hyaloid; T1 (A), T2 (B), and T3(C)	22
(15)	Distribution of the studied cases according to sex	34
(16)	Distribution of the studied cases according to age	34
(17)	Distribution of the studied cases according to type of DM	35
(18)	Mean, standard deviation and range of visual acuity before IVTA injection and after one month and six months from IVTA injection.	37

Figure		Page
(19)	Mean, standard deviation and range of retinal thickness in central subfield zone before IVTA injection and after one month and six months from IVTA injection.	39
(20)	Mean, standard deviation and range of PROS length in macular grid zone before IVTA injection and after one month and six months from IVTA injection.	42
(21)	Mean, standard deviation and range of PROS length in central subfield zone before IVTA injection and after one month and six months from IVTA injection	44
(22)	Mean, standard deviation and range of PROS length in central foveal point before IVTA injection and after one month and six months from IVTA injection.	46
(23)	Correlation between VA with retinal thickness in the central subfield zone before IVTA injection and after 1 and 6 month	47
(24)	Correlation between VA and PROS in CS before IVTA injection and after 1 and 6 month	48
(25)	Case 1. OCT scan (pre-IVTA injection, 1 and 6months after IVTA injection). Macular thickness maps both numerical and colour	49
(26)	Case 2. OCT scans (pre-IVTA injection, 1 and 6 months after IVTA injection). Macular thickness maps both numerical and colour.	50

LIST OF ABBREVIATIONS

AGEs	: Advanced glycation end products
AR	: Aldose reductase
BCVA	: Best corrected visual acuity
bFGF	: Basic fibroblast growth factor
CF	: Central foveal point
CFP	: Central foveal point.
CMT	: Central macular thickness
CS	: Central subfield
CSF	: Central subfield
CSME	: Clinically significant macular edema
D	: Diopter
DCCT	: Diabetes Control and Complications trial
DM	: Diabetes mellitus
DME	: Diabetic macular edema
DR	: Diabetic retinopathy
DRS	: Diabetic retinopathy study
DRT	: Diffuse retinal thickening
DRVS	: Diabetic retinopathy vitrectomy study
ERG	: Electroretinogram
ETDRS	: Early treatment diabetic retinopathy study
FA	: Fluorescein angiography
FAZ	: Foveal avascular zone
FD	: Fourier domain
FPD	: Fibrous proliferation on the disc
FPE	: Fibrous proliferation elsewhere
GH	: Growth hormone
HbA1C	: Glycosylated hemoglobin
HR PDR	: High risk proliferative diabetic retinopathy
HTN	: Hypertension
IOL	: Intraocular lens implantation
IOP	: Intraocular pressure
IRMA	: Intra-retinal micro-vascular abnormalities
IV TA	: Intra-vitreous Triamcinolone acetonide
ME	: Macular edema
Mg	: Milligram
MG	: Macular grid
MG	: Macular grid
Mm	: Millimeter
N	: Number of the studied sample
Nd:Yag	: Neodymium yttrium aluminium garnet laser

NPDR	: Non-proliferative diabetic retinopathy
NVDs	: New vessels of the disc
NVEs	: New vessels elsewhere
OCT	: Optical coherence tomography
PDGF	: Platelet derived growth factor
PDR	: Proliferative diabetic retinopathy
PEDF	: Pigment epithelium derived factor
PHM	: Posterior hyaloid membrane
PHT	: Posterior hyaloid traction
PKC	: Protein kinase c
PPV	: Pars plana vitrectomy
PRH	: Pre-retinal hemorrhage
PROS	: Photoreceptor outer segment
PRP	: Pan retinal laser photocoagulation
PVD	: Posterior vitreous detachment
RPE	: Retinal pigment epithelium
RT	: Retinal thickness
RTA	: Retinal thickness analyzer
SD	: Standard deviation
SLO	: Scanning laser ophthalmoscope
SRD	: Serous retinal detachment
TA	: Triamcinolone acetonide
TGFB	: Transforming growth factor beta
TRD	: Tractional retinal detachment
TRD/RRD	: Combined tractional rhegmatogenous retinal detachment
U	: Mann-whitney
UKPDS	: United kingdom prospective diabetes study
VA	: Visual acuity
VEGF	: Vascular endothelial growth factor
VF	: Vitreous fluorophotometry
VH	: Vitreous hemorrhage
WDRS	: Wisconsin diabetes registry study
WESDR	: Wisconsin Epidemiologic Study of Diabetic Retinopathy
µm	: Micrometer
χ²	: Chi-squar